The present invention reveals human recombinant antibodies that recognize the human Vascular Endothelium Growth Factor A (VEGF-A), block its interaction with the VEGFR2 receptor, and interfere with its proliferative effect in vitro and pro-angiogenic effect in vivo. The antibodies identify an epitope on human VEGF-A different from any other previously reported, and were obtained by combining one immunoglobulin light chain variable region with other three heavy chain ones. The antibodies were obtained by human immunoglobulin variable region mutagenesis, and can be employed for the immunotherapy of pathological entities associated with an increase in vasculature, such as age-related macular degeneration, cancer, and others.本發明展現人類重組抗體,其等辨識人類血管內皮生長因子A(VEGF-A)、阻斷其與VEGFR2受體之交互作用,以及干擾其之活體外增殖作用和活體內促血管生成作用。該等抗體識別不同於任何其他先前的報告的人類VEGF-A上之一抗原決定位,以及係藉由組合一個免疫球蛋白輕鏈變異區與其他的三個重鏈變異區所獲得。該等抗體係藉由人類免疫球蛋白變異區突變所獲得的,以及可以使用於血管分佈之增加有關聯的病理實體,例如老年性黃斑部退化、癌症,和其他的,之免疫療法。
